Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAK Cells vs Gliadel Wafer in Newly Diagnosed Resectable Glioblastoma
NCT00814593Phase 2Withdrawn
- Sponsor
- Lisata Therapeutics
- Start
- Nov 2008
- Primary completion
- Apr 2011
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of lymphokine-activated killer cells in glioblastoma (GBM), sponsored by Lisata Therapeutics. Planned start Nov 2008; status: withdrawn.
02
Drugs
lymphokine-activated killer cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00814593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00814593.